Wechselwirkungen · Epidyolex
Epidyolex 100 mg/ml oral solution · Abschnitt 4.5 · PDF-Seite 8
HOS-140619 · Präparat HOS-098554
Sensitive substrates of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, UGT1A9, and UGT2B7 Sensitive CYP1A2 substrates In vivo data from steady-state dosing with cannabidiol (750 mg twice daily) when co-administered with a single dose of caffeine (200 mg), a sensitive CYP1A2 substrate, showed increased caffeine exposure by 15% for Cmax and 95% for AUC compared to when caffeine was administered alone. These data indicate that cannabidiol is a weak inhibitor of CYP1A2. Similar modest increases in exposure may be observed with other sensitive CYP1A2 substrates (e.g., theophylline or tizanidine). The clinical importance of these findings has not been studied. The patient should be closely monitored for adverse drug reactions.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tizanidine (HOS-089668) caffeine (HOS-085902) theophylline (HOS-085910)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-20T11:14:00Z · SHA-256 ccb7fce36b37a5c512676c2475ea9ab250d2fd66d8e1f76a5048e693726825e9 · Passage d2876c92e6439dd10450c189bb4651ea779c5c869115eba02721133b071fce67 · Zeichen 4760–5484 im Abschnitt